Preeclampsia is a serious cardiovascular disorder of pregnancy characterised by high blood pressure. It threatens maternal and fetal health through complications including poor fetal growth, preterm birth and stillbirth.
Women who experience preeclampsia face a significantly higher risk of developing cardiovascular disease later in life.
Early detection of preeclampsia is crucial to initiate medical interventions that dramatically improve health outcomes for mothers and babies.
Our team has developed a prototype point-of-care test for quantitative detection of biomarkers that indicate placental vascular dysfunction, enabling prediction of preeclampsia >1 month before clinical symptoms appear. The test is specifically designed for community-based maternal care settings.
This world-first rapid, low-cost diagnostic will enable widespread early testing to reduce complications from preeclampsia and long-term cardiovascular consequences.
Point-of-care test results in 15-30 minutes represent a critical advancement in protecting the health of women and babies during pregnancy and throughout their lives.
TTRA Project: Devices
State: VIC
Project Partners:
Project Lead: Dr Riikka Arppe-Tabbara
TTRA Funding: $1,019,134.00
Co-Contribution: $1,019,134.00 cash; $1,148,907.00 in-kind
Project term: 1 July 2025 – 30 June 2027
